BENEVOLENTAI
Company Snapshot
Founded: 2013
Entity Type: Private
Region: U.K.
Headquarter: Luxembourg, U.K.
Key Geographics: U.K., European Union
Corporate Address: 9 rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg, U.K. Tel: +44-(0)20-3781-9360 Web: www.benevolent.com
Company Overview
Based in Luxembourg with additional labs in Cambridge, England and an office in New York, BenevolentAI is a clinical-stage biotech company that uses wet-lab capabilities and proprietary AI to expedite drug discovery and development. Its Benevolent Platform combines biomedical data to predict new targets, discover new biology, and create possible drug candidates. The platform supports its in-house pipeline, which includes several preclinical and clinical programs like BEN-8744 for ulcerative colitis, as well as partnerships with pharmaceutical firms such as AstraZeneca, Merck and Eli Lilly.
BENEVOLENTAI In News
Company's Business Segments
- Drug Discovery : This segment offers AI-enabled drug discovery platform and helps scientists in successful discovery of drugs.
Applications/End User Industries
- Pharmaceuticals
- Life Sciences